We are building a deep and compelling pipeline of product candidates with the potential to advance care and outcomes for patients with diverse autoimmune or inflammatory diseases
- Discovery /Pre-clinical
- Phase I
- Phase II
- PIVOTAL OR PHASE III
NEXT ANTICIPATED MILESTONE
Antibody targeting IL-4Rα cytokine receptor
(Th2 cell modulator)
Atopic Dermatitis (AD) - China
Atopic Dermatitis (AD) - Global
Asthma - Global
- Pivotal trial Stage 2 readout in Q4’23 & NDA by end of Q1’24
- Seeking partnership to advance Global Ph3
- Topline readout in Q4’23
Small molecule targeting S1P1 (Th1 cell modulator)
Ulcerative Colitis
Crohn's Disease
- Maintenance data reported Q2’2023
- Seeking partnerships to advance into future trials for both indications
CBP-233
IL-33 mAb
Type 2 Inflammatory Diseases
- To initiate IND-enabling studies in H1 2024
CBP-246
Antibody targeting IL-1RAcP
Type 2 Inflammatory Diseases
- To initiate IND-enabling studies in 2H 2023
CBP-403
Bispecific mAb targeting Th2 cytokines
Type 2 Inflammatory Diseases
- Development candidate nomination in 2H 2023